Generally, therapeutic strategies through modulating FABP4 expression, fatty acids levels, or CXCL10 production may be effective for T1D with the elimination of TRM cell‐mediated cytotoxic T cell recruitment and the subsequent β cell death. This evidence concerns the gene FABP4 and type 1 diabetes mellitus.